Human amniotic fluid source organoid in-vitro culture medium, in-vitro culture method and application
By providing an in vitro culture medium of human amniotic fluid-derived organoids containing components such as GDNF, 8-Br-cAMP and aldosterone, the problem that the prior art cannot effectively utilize human amniotic fluid cells for in vitro three-dimensional culture is solved, and efficient culture and differentiation is achieved , a model of generating multi-type functional cells is suitable for studying early fetal developmental diseases.
Patent Information
- Application Number
- CN202411347295.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-26
- Publication Date
- 2025-02-14
AI Technical Summary
The prior art cannot effectively utilize cells in human amniotic fluid for three-dimensional culture in vitro to construct an organoid model, which limits the prenatal research of fetal development and congenital diseases.
Provides an in vitro culture medium of human amniotic fluid-derived organoids, including glial cell-derived neurotrophic factor (GDNF), 8-bromodase-3',5'-cyclic monophosphate (8-Br-cAMP), and aldosterone ( Aldosterone) and other ingredients, and formulate corresponding in vitro culture and differentiation methods.
It has achieved efficient culture and differentiation of human amniotic fluid-derived organoids, and generated a model containing multi-type functional cells such as neuron-like cells and cardiomyocytes. Its differentiation ability is better than the existing 2D cell line model and can be passed down for a long time and stable, suitable for Study on early developmental diseases of human fetals.
Smart Images

Figure CN119432721A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of in vitro cell culture, and specifically relates to an in vitro culture medium, in vitro culture method and application of human amniotic fluid-derived organoids. Background Art
[0002] Organoids are three-dimensional structural models with original tissues and organs formed through in vitro 3D culture, which can highly simulate the structure and function of organs in the human body. They are usually derived from pluripotent stem cells (PSCs) or adult stem cells, and have the ability to self-renew and self-organize, thus performing organ functions similar to the original tissue.
[0003] At present, tissue-derived fetal stem cells or organoids can only be isolated or cultured from samples obtained after termination of pregnancy, such as umbilical cord or placental mesenchymal stem cells, placental trophoblast organoids, etc., but these stem cell or organoid models cannot be used for prenatal research on fetal development and congenital diseases. Therefore, it is necessary to establish new in vitro models that can simulate patient-specific characteristics earlier. Based on this, it would be a better choice if stem cells could be isolated during pregnancy without tissue samples. Amniotic fluid is the cell source of multiple developing organs. The cells in amniotic fluid contain stem cells or progenitor cells for the development of various organs, and are consistent with the timeline of fetal development. If the cells contained in amniotic fluid can be isolated and cultured in three dimensions, an amniotic fluid-derived organoid model can be constructed, which is conducive to providing an ideal in vitro research model for studying the mechanisms and diagnosis and treatment techniques of fetal development-related diseases.
[0004] CN111759864B discloses an application of amniotic fluid stem cells in the preparation of drugs for treating lupus nephritis. This patent mainly separates, cultures and identifies amniotic fluid stem cells from human mid-pregnancy amniotic fluid, and finds that amniotic fluid stem cells can reduce the level of urinary protein in lupus mice. The amniotic fluid stem cells are mainly mesenchymal stem cells obtained by adherent culture, and three-dimensional culture is not performed to obtain an organoid model. The mesenchymal stem cells cultured by adherent culture are of a single type, are very easy to mutate, and cannot be cultured for a long time. They are not ideal in vitro amniotic fluid stem cell models, and their application range is extremely limited. At present, no in vitro culture medium for organoids derived from human amniotic fluid, and corresponding in vitro culture and differentiation methods have been found. Summary of the invention
[0005] In view of this, the main purpose of the present invention is to provide an in vitro culture medium, in vitro culture method and application of human amniotic fluid-derived organoids, in order to at least partially solve the above-mentioned technical problems.
[0006] In order to achieve the above-mentioned object, as a first aspect of the present invention, a human amniotic fluid-derived organoid in vitro culture medium is provided, comprising the following components:
[0007] Glial cell line-derived neurotrophic factor (GDNF), 8-bromoadenosine-3',5'-cyclic monophosphate (8-Br-cAMP), and aldosterone.
[0008] Preferably, in the in vitro culture medium of human amniotic fluid-derived organoids, the working concentrations of GNDF, 8-Br-cAMP and aldosterone are:
[0009] The concentration of GNDF is 100-200 ng / mL, for example, it can be 100 ng / mL, 110 ng / mL, 120 ng / mL, 130 ng / mL, 140 ng / mL, 150 ng / mL, 160 ng / mL, 170 ng / mL, 180 ng / mL, 190 ng / mL, 200 ng / mL or any value in the range, which will not be described due to space limitations. GNDF is a glial cell-derived neurotrophic factor, and its mode of action is mainly target-derived, and there may also be paracrine and autocrine modes of action. GDNF has a strong effect and has a broader spectrum of neurotrophic effects.
[0010] The concentration of 8-Br-cAMP is 3-10 μM, for example, 3 μM, 3.5 μM, 4 μM, 4.5 μM, 5 μM, 5.5 μM, 6 μM, 6.5 μM, 7 μM, 7.5 μM, 8 μM, 8.5 μM, 9 μM, 9.5 μM, 10 μM or any value in the range, which will not be described in detail due to space limitations. 8-Br-cAMP is a cell-permeable cAMP analog that has stronger resistance to phosphodiesterase hydrolysis than cAMP. 8-Bromoadenosine-3′,5′-cyclic monophosphate can activate protein kinase A, inhibit growth, reduce proliferation, increase differentiation and induce apoptosis of cultured cells.
[0011] The concentration of aldosterone is 10-30nM, for example, it can be 10mM, 11mM, 12mM, 13mM, 14mM, 15mM, 16mM, 17mM, 18mM, 19mM, 20mM, 21mM, 22mM, 23mM, 24mM, 25mM, 26mM, 27mM, 28mM, 29mM, 30mM or any value in the said range, which will not be described in detail due to space limitations.
[0012] Preferably, the human amniotic fluid-derived organoid in vitro culture medium further comprises:
[0013] DMEM-F12 basal medium, 4-hydroxyethylpiperazineethanesulfonic acid (HEPES), B-27 supplement (minus vitamin A), glutamine (Glutamine, Gln), WNT-3a, R-Spondin-1 protein (RSPO1), Noggin protein and nicotinamide.
[0014] Preferably, in the human amniotic fluid-derived organoid in vitro culture medium, the working concentrations of 4-hydroxyethylpiperazineethanesulfonic acid (HEPES), B-27 additive (minus vitamin A), glutamine (Glutamine, Gln), WNT-3a, R-Spondin-1, Noggin and nicotinamide are:
[0015] The concentration of HEPES is 10-50mM, and its concentration can be 10mM, 12.5mM, 15mM, 17.5mM, 20mM, 22.5mM, 25mM, 27.5mM, 30mM, 32.5mM, 35mM, 37.5mM, 40mM, 42.5mM, 45mM, 47.5mM, 50mM or any value in the range, which will not be described in detail due to space limitations. HEPES is a commonly used zwitterionic buffer with a pKa of 7.3 at 37°C, which maintains sufficient bicarbonate in the culture medium for nutritional purposes to provide additional buffering capacity. Lower concentrations are usually insufficient to control pH fluctuations, while higher concentrations are usually toxic.
[0016] B-27 Supplement - Vitamin A removed by volume fraction of 1%-2%, which volume fraction can be 1%, 1.05%, 1.1%, 1.15%, 1.2%, 1.25%, 1.3%, 1.35%, 1.4%, 1.45%, 1.5%, 1.55%, 1.6%, 1.65%, 1.7%, 1.75%, 1.8%, 1.85%, 1.9%, 1.95%, 2% or any value within the range, which will not be described in detail due to space limitations. B-27 Supplement is an optimized serum-free supplement used to support the growth and activity maintenance of embryonic, postnatal and adult hippocampal neurons and other central nervous system (CNS) neurons.
[0017] The concentration of glutamine is 2-10mM, for example, it can be 2mM, 2.5mM, 3mM, 3.5mM, 4mM, 4.5mM, 5mM, 5.5mM, 6mM, 6.5mM, 7mM, 7.5mM, 8mM, 8.5mM, 9mM, 9.5mM, 10mM or any value in the said range, which is not described again due to space limitations.
[0018] The concentration of WNT-3a is 200-500ng / mL, for example, it can be 200ng / mL, 225ng / mL, 250ng / mL, 275ng / mL, 300ng / mL, 325ng / mL, 350ng / mL, 375ng / mL, 400ng / mL, 425ng / mL, 450ng / mL, 475ng / mL, 500ng / mL or any value in the range, which will not be repeated due to space limitations. Wnt-3a is the most representative signaling protein of the Wnt family. It is widely distributed and plays a key role in regulating pleiotropic cell functions (including self-renewal, proliferation, differentiation and movement). It is also one of the most commonly used culture factors for organoid construction. Its high activity, batch-to-batch stability, pollution-free and serum-free preparation are the key to the success of organoid experiments, so high-quality cytokines are essential for the culture of organoids.
[0019] The concentration of R-Spondin-1 protein is 300-500ng / mL, for example, it can be 300ng / mL, 325ng / mL, 350ng / mL, 375ng / mL, 400ng / mL, 425ng / mL, 450ng / mL, 475ng / mL, 500ng / mL or any value in the said range, which will not be repeated due to space limitations. R-Spondin-1 protein is a member of the R-spondin family, RSPO1 has about 40% amino acid identity with the other three R-Spondin family members, which is a microenvironmental factor that maintains adult stem cells in multiple organs. RSPO1 is a secreted activating protein with two cysteine-rich furin-like domains (FU-like CR) and a thrombospondin type 1 domain (TSR). RSPO1, as a canonical Wnt signal enhancer, is currently widely used to promote the growth and survival of 3D organoids.
[0020] The concentration of Noggin protein is 100-300ng / mL, for example, it can be 100ng / mL, 110ng / mL, 120ng / mL, 130ng / mL, 140ng / mL, 150ng / mL, 160ng / mL, 170ng / mL, 180ng / mL, 190ng / mL, 200ng / mL, 210ng / mL, 220ng / mL, 230ng / mL, 240ng / mL, 250ng / mL, 260ng / mL, 270ng / mL, 280ng / mL, 290ng / mL, 300ng / mL or any value in the range, which will not be described due to space limitations. Noggin can specifically bind to and inhibit BMPs, plays an important role in early embryonic development, limb formation and nervous system development, and at the same time, antagonizes BMPs to affect the normal development of bones, cartilage and joints.
[0021] The concentration of nicotinamide is 2-10 mM, for example, 2 mM, 2.5 mM, 3 mM, 3.5 mM, 4 mM, 4.5 mM, 5 mM, 5.5 mM, 6 mM, 6.5 mM, 7 mM, 7.5 mM, 8 mM, 8.5 mM, 9 mM, 9.5 mM, 10 mM or any value within the range, which will not be described in detail due to space limitations.
[0022] Preferably, the human amniotic fluid-derived organoid in vitro culture medium further comprises:
[0023] CHIR 99021 (GSK-3α / β inhibitor), epidermal growth factor (EGF), A83-01 (inhibitor of TGF-β type I receptor ALK5, ALK4 and ALK7), gastrin, Y-27632 (ROCK inhibitor); and / or penicillin-streptomycin.
[0024] Preferably, in the in vitro culture medium of human amniotic fluid-derived organoids, the working concentrations of CHIR 99021 (GSK-3α / β inhibitor), epidermal growth factor (EGF), A83-01, gastrin, and Y-27632 (ROCK inhibitor) are:
[0025] The concentration of CHIR99021 is 10-50 μM, for example, it can be 10 μM, 12.5 μM, 15 μM, 17.5 μM, 20 μM, 22.5 μM, 25 μM, 27.5 μM, 30 μM, 32.5 μM, 35 μM, 37.5 μM, 40 μM, 42.5 μM, 45 μM, 47.5 μM, 50 μM or any value within the said range, which will not be elaborated here due to space limitations. CHIR99021 is a highly effective inhibitor of GSK-3α (IC50: 10nM) and GSK-3β (IC50: 6.7nM). The selectivity of CHIR-99021 for GSK-3 is more than 500 times higher than the closest homologs CDC2, ERK2 and other protein kinases. CHIR-99021 can activate the Wnt / β-catenin signaling pathway and induce the cardiomyogenic differentiation of embryonic stem cells.
[0026] The concentration of EGF is 100-300ng / mL, for example can be 100ng / mL, 110ng / mL, 120ng / mL, 130ng / mL, 140ng / mL, 150ng / mL, 160ng / mL, 170ng / mL, 180ng / mL, 190ng / mL, 200ng / mL, 210ng / mL, 220ng / mL, 230ng / mL, 240ng / mL, 250ng / mL, 260ng / mL, 270ng / mL, 280ng / mL, 290ng / mL, 300ng / mL or any value of described scope, owing to the limitation of space, no longer repeat them.EGF is epidermal growth factor, plays an important role in regulating cell growth, proliferation and differentiation.Epidermal growth factor is a kind of little peptide, is made up of 53 amino acid residues, is a member of the large family of class EGF. EGF binds to specific receptors on the surface of responsive cells. Once bound, it promotes receptor dimerization and phosphorylation of cytoplasmic sites. The activated receptor can bind to at least 5 proteins with different signal sequences to conduct signal transduction and regulate protein synthesis. In addition, EGF can increase the activity of DNA topoisomerase in cells and promote the expression of some genes related to proliferation, such as myc, fos, etc.
[0027] The concentration of A83-01 is 5-20 μM, for example, it can be 5 μM, 6 μM, 7 μM, 8 μM, 9 μM, 10 μM, 11 μM, 12 μM, 13 μM, 14 μM, 15 μM, 16 μM, 17 μM, 18 μM, 19 μM, 20 μM or any value in the range, which will not be described due to space limitations. A83-01 is an inhibitor of TGF-β type I receptor ALK5, ALK4 and ALK7, and an inhibitor of the Activin / NODAL / TGF-beta pathway.
[0028] The concentration of gastrin is 5-20nM, for example, it can be 5nM, 6nM, 7nM, 8nM, 9nM, 10nM, 11nM, 12nM, 13nM, 14nM, 15nM, 16nM, 17nM, 18nM, 19nM, 20nM or any value in the range, which will not be described due to space limitations. Gastrin is an important polypeptide hormone in the gastrointestinal tract, mainly secreted by G cells. When culturing intestinal and liver organoids in the prior art, adding gastrin mainly serves to prolong the survival time of the organoids.
[0029] The concentration of Y-27632 is 10-20 μM, for example, it can be 10 μM, 10.5 μM, 11 μM, 11.5 μM, 12 μM, 12.5 μM, 13 μM, 13.5 μM, 14 μM, 14.5 μM, 15 μM, 15.5 μM, 16 μM, 16.5 μM, 17 μM, 17.5 μM, 18 μM, 18.5 μM, 19 μM, 19.5 μM, 20 μM or any value in the range, which will not be described due to space limitations. Y27632 is a small molecule specific inhibitor of the Rho-associated serine-threonine protein kinase (ROCK) family, which can prevent apoptosis of stem cells.
[0030] Preferably, the human amniotic fluid-derived organoid in vitro culture medium also includes 0.1%-1% penicillin-streptomy by volume, which serves the purpose of antibacterial during the culture process. The volume fraction of penicillin-streptomycin can be 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1% or any value in the range, which will not be repeated due to space limitations.
[0031] As a second aspect of the present invention, a method for culturing human amniotic fluid-derived organoids in vitro is provided, comprising the following steps:
[0032] Step 1: Primary culture:
[0033] Collecting human amniotic fluid cells, and adding the human amniotic fluid-derived organoid in vitro culture medium as described in the first aspect for culture, and obtaining primary amniotic fluid organoids after 10-14 days;
[0034] Step 2: Clone and create:
[0035] The culture medium of the primary amniotic fluid organoids was removed, ThypLE express enzyme was added for digestion, DMEM-F12 basal culture medium was added, and the organoid cell clusters were blown apart into single cells, filtered, resuspended, and counted, and then the human amniotic fluid-derived organoid in vitro culture medium as described in the first aspect was added for culture, and a successfully established organoid clone was obtained after 10-14 days;
[0036] Step 3: Subculture to obtain amniotic fluid organoids derived from single cells.
[0037] Among them, the number of days in step one can be 10d, 10.5d, 11d, 11.5d, 12d, 12.5d, 13d, 13.5d, 14d or any value in the range, which will not be elaborated again due to space limitations.
[0038] The number of days in step 2 may be 10d, 10.5d, 11d, 11.5d, 12d, 12.5d, 13d, 13.5d, 14d or any value within the range, which will not be described herein again due to space limitations.
[0039] Preferably, the digestion temperature in step 2 is 36-40°C (for example, it can be 36°C, 36.5°C, 37°C, 37.5°C, 38°C, 38.5°C, 39°C, 39.5°C, 40°C or any value in the range, which will not be repeated due to space limitations), and the digestion time is 30-60min (for example, it can be 30min, 35min, 40min, 45min, 50min, 55min, 60min or any value in the range, which will not be repeated due to space limitations);
[0040] Preferably, the filtration in step 2 is performed by filtering with a cell sieve with a pore size of 40-100 μm (the pore size of the cell sieve can be 40 μm, 45 μm, 50 μm, 55 μm, 60 μm, 65 μm, 70 μm, 75 μm, 80 μm, 85 μm, 90 μm, 95 μm, 100 μm or any value in the said range, which will not be described in detail due to space limitations) to obtain a cell suspension, the purpose of which is to remove incompletely digested cell clusters in the organoid cell suspension.
[0041] Preferably, the resuspension in step 2 is to centrifuge the cell suspension, remove the supernatant, add DMEM-F12 basal culture medium, and then resuspend; wherein the centrifugation conditions are: 4°C, 1200rpm, 5 minutes.
[0042] Preferably, the culture described in step 2 is specifically as follows: according to the cell counting results, a total of 100 single cells are taken and mixed thoroughly with 2.5 mL of pre-cooled matrix gel (Corning Matrigel matrix); 1 drop per well, 25 μL / well, is added to a 96-well plate, and the 96-well plate is transferred to an incubator for 20-30 minutes; after the matrix gel containing amniotic fluid cells is fully solidified, 150 μL of the human amniotic fluid-derived organoid in vitro culture medium as described in the first aspect is added to each well, and the culture medium is changed every 3 days.
[0043] Preferably, the method for culturing human amniotic fluid-derived organoids in vitro comprises the following steps:
[0044] Step 1: Primary culture:
[0045] Collecting human amniotic fluid cells, and adding the human amniotic fluid-derived organoid in vitro culture medium described in any one of claims 1 to 4 for culturing, and obtaining primary amniotic fluid organoids after 10 to 14 days;
[0046] Step 2: Clone and create:
[0047] The culture medium of the primary amniotic fluid organoids was removed, ThypLE express enzyme was added for digestion, DMEM-F12 basal culture medium was added, and the organoid cell clusters were blown into single cells, and filtered with a cell sieve with a pore size of 40-100 μm; the cell suspension was centrifuged, the supernatant was removed, DMEM-F12 basal culture medium was added, and then the cell suspension was resuspended and counted, and then the in vitro culture medium of human amniotic fluid-derived organoids described in any one of claims 1 to 4 was added for culturing, and a successfully established organoid clone was obtained after 10-14 days;
[0048] Step 3: Subculture to obtain amniotic fluid organoids derived from single cells.
[0049] As a third aspect of the present invention, there is provided a use of the human amniotic fluid-derived organoid in vitro culture medium as described in the first aspect in the in vitro culture of human cell organoids.
[0050] Based on the above technical solutions, it can be seen that the human amniotic fluid-derived organoid in vitro culture medium and culture and differentiation method of the present invention have at least one of the following beneficial effects compared with the prior art:
[0051] The method provided by the present invention is simple to operate, the components of the in vitro culture medium are clear, and the success rate of culture is high. The human amniotic fluid organoids cultured using the culture medium and method of the present invention can be differentiated into multiple types of functional cells including neuron-like cells, cardiomyocytes, etc. after induction in vitro, and the differentiation ability is significantly better than the existing 2D cell line model. In addition, the single-cell-derived amniotic fluid organoid model constructed by the method of the present invention can be stably propagated for a long time, and is suitable as an in vitro research model for studying early developmental diseases of the human fetus. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 This is a statistics of the number of organoid cells obtained using different amniotic fluid organoid culture medium formulations.
[0053] Figure 2 This is a growth chart of amniotic fluid organoid culture using different concentrations of culture medium.
[0054] Figure 3 This is the growth morphology of the primary cultured amniotic fluid organoids in Example 3 on days 0, 5, 10, and 14.
[0055] Figure 4 This is the growth morphology of the amniotic fluid organoid clone derived from a single cell in Example 4 after 14 days of culture.
[0056] Figure 5 These are the RT-PCR test results of the specific genes neurogenic differentiation factor 4 (Neurod4) and neuronal class III β-tubulin (Tuj1) after the amniotic fluid organoids differentiated into neurons.
[0057] Figure 6 These are the RT-PCR test results of the specific genes T-box transcription factor 5 (Tbx5) and GATA binding protein 4 (GATA4) after the amniotic fluid organoids differentiated into cardiomyocytes.
[0058] Figure 7 These are the RT-PCR detection results of the specific genes α-myosin heavy chain (α-MHC) and homeobox transcription factor NKX 2.5 (Nkx 2.5) after amniotic fluid organoids differentiated into cardiomyocytes. DETAILED DESCRIPTION
[0059] The human amniotic fluid-derived cell culture in the prior art is limited to a 2D cell line model with limited differentiation ability. After intensive research, the inventors of the present invention have improved the above steps to obtain a single-cell-derived amniotic fluid organoid model with better differentiation ability. Specifically, as a first aspect of the present invention, a human amniotic fluid-derived organoid in vitro culture medium is provided, comprising the following components:
[0060] DMEM-F12 basal culture medium, glial cell line-derived neurotrophic factor (GDNF), 8-bromoadenosine-3',5'-cyclic monophosphate (8-Br-cAMP), and aldosterone.
[0061] In a preferred embodiment, the human amniotic fluid-derived organoid in vitro culture medium further comprises:
[0062] 4-Hydroxyethylpiperazineethanesulfonic acid (HEPES), B-27 supplement (minus vitamin A), Glutamine (Gln), WNT-3a, R-Spondin-1, Noggin and Nicotinamide.
[0063] In a preferred embodiment, the human amniotic fluid-derived organoid in vitro culture medium further comprises:
[0064] CHIR 99021 (GSK-3α / β inhibitor), epidermal growth factor (EGF), A83-01, gastrin, Y-27632 (ROCK inhibitor); and / or penicillin-streptomycin.
[0065] In a preferred embodiment, the working concentrations of GNDF, 8-Br-cAMP and aldosterone in the human amniotic fluid-derived organoid in vitro culture medium are:
[0066] 100-200 ng / mL GNDF can be, for example, 100 ng / mL, 110 ng / mL, 120 ng / mL, 130 ng / mL, 140 ng / mL, 150 ng / mL, 160 ng / mL, 170 ng / mL, 180 ng / mL, 190 ng / mL, 200 ng / mL or any value in the said range, which is not described again due to space limitations.
[0067] 3-10μM 8-Br-cAMP, for example, can be 3μM, 3.5μM, 4μM, 4.5μM, 5μM, 5.5μM, 6μM, 6.5μM, 7μM, 7.5μM, 8μM, 8.5μM, 9μM, 9.5μM, 10μM or any value in the said range, which will not be elaborated again due to space limitations.
[0068] 10-30nM aldosterone can be, for example, 10mM, 11mM, 12mM, 13mM, 14mM, 15mM, 16mM, 17mM, 18mM, 19mM, 20mM, 21mM, 22mM, 23mM, 24mM, 25mM, 26mM, 27mM, 28mM, 29mM, 30mM or any value in the said range, which will not be described in detail due to space limitations.
[0069] Preferably, in the in vitro culture medium of human amniotic fluid-derived organoids, the working concentrations of CHIR 99021 (GSK-3α / β inhibitor), epidermal growth factor (EGF), A83-01, gastrin, and Y-27632 (ROCK inhibitor) are:
[0070] 10-50μM CHIR99021, for example, can be 10μM, 12.5μM, 15μM, 17.5μM, 20μM, 22.5μM, 25μM, 27.5μM, 30μM, 32.5μM, 35μM, 37.5μM, 40μM, 42.5μM, 45μM, 47.5μM, 50μM or any value in the said range, which will not be elaborated here due to space limitations.
[0071] 100-300ng / mL of EGF can be, for example, 100ng / mL, 110ng / mL, 120ng / mL, 130ng / mL, 140ng / mL, 150ng / mL, 160ng / mL, 170ng / mL, 180ng / mL, 190ng / mL, 200ng / mL, 210ng / mL, 220ng / mL, 230ng / mL, 240ng / mL, 250ng / mL, 260ng / mL, 270ng / mL, 280ng / mL, 290ng / mL, 300ng / mL or any value in the said range, which is not described in detail due to space limitations.
[0072] 5-20μM A83-01 can be, for example, 5μM, 6μM, 7μM, 8μM, 9μM, 10μM, 11μM, 12μM, 13μM, 14μM, 15μM, 16μM, 17μM, 18μM, 19μM, 20μM or any value in the said range, which will not be described again due to space limitations.
[0073] 5-20 nM gastrin can be, for example, 5 nM, 6 nM, 7 nM, 8 nM, 9 nM, 10 nM, 11 nM, 12 nM, 13 nM, 14 nM, 15 nM, 16 nM, 17 nM, 18 nM, 19 nM, 20 nM or any value in the said range, which will not be described in detail due to space limitations.
[0074] 10-20μM Y-27632 can be, for example, 10μM, 10.5μM, 11μM, 11.5μM, 12μM, 12.5μM, 13μM, 13.5μM, 14μM, 14.5μM, 15μM, 15.5μM, 16μM, 16.5μM, 17μM, 17.5μM, 18μM, 18.5μM, 19μM, 19.5μM, 20μM or any value in the said range, which will not be elaborated here due to space limitations.
[0075] In a preferred embodiment, in the human amniotic fluid-derived organoid in vitro culture medium, the working concentrations of 4-hydroxyethylpiperazineethanesulfonic acid (HEPES), B-27 additive (minus vitamin A), glutamine (Glutamine, Gln), WNT-3a, R-Spondin-1, Noggin and nicotinamide are:
[0076] 10-50mM HEPES, its concentration can be 10mM, 12.5mM, 15mM, 17.5mM, 20mM, 22.5mM, 25mM, 27.5mM, 30mM, 32.5mM, 35mM, 37.5mM, 40mM, 42.5mM, 45mM, 47.5mM, 50mM or any value in the said range, which is not described again due to space limitations.
[0077] B-27 additive with a volume fraction of 1%-2% - vitamin A removed, its volume fraction can be 1%, 1.05%, 1.1%, 1.15%, 1.2%, 1.25%, 1.3%, 1.35%, 1.4%, 1.45%, 1.5%, 1.55%, 1.6%, 1.65%, 1.7%, 1.75%, 1.8%, 1.85%, 1.9%, 1.95%, 2% or any value in the said range, which will not be elaborated due to space limitations.
[0078] 2-10 mM glutamine, for example, can be 2 mM, 2.5 mM, 3 mM, 3.5 mM, 4 mM, 4.5 mM, 5 mM, 5.5 mM, 6 mM, 6.5 mM, 7 mM, 7.5 mM, 8 mM, 8.5 mM, 9 mM, 9.5 mM, 10 mM or any value in the said range, which will not be described again due to space limitations.
[0079] 200-500 ng / mL of WNT-3a can be, for example, 200 ng / mL, 225 ng / mL, 250 ng / mL, 275 ng / mL, 300 ng / mL, 325 ng / mL, 350 ng / mL, 375 ng / mL, 400 ng / mL, 425 ng / mL, 450 ng / mL, 475 ng / mL, 500 ng / mL or any value in the said range, which is not described again due to space limitations.
[0080] 300-500 ng / mL of R-Spondin-1 can be, for example, 300 ng / mL, 325 ng / mL, 350 ng / mL, 375 ng / mL, 400 ng / mL, 425 ng / mL, 450 ng / mL, 475 ng / mL, 500 ng / mL or any value within the said range, which will not be described in detail due to space limitations.
[0081] 100-300 ng / mL of Noggin can be, for example, 100 ng / mL, 110 ng / mL, 120 ng / mL, 130 ng / mL, 140 ng / mL, 150 ng / mL, 160 ng / mL, 170 ng / mL, 180 ng / mL, 190 ng / mL, 200 ng / mL, 210 ng / mL, 220 ng / mL, 230 ng / mL, 240 ng / mL, 250 ng / mL, 260 ng / mL, 270 ng / mL, 280 ng / mL, 290 ng / mL, 300 ng / mL or any value in the said range, which is not described again due to space limitations.
[0082] 2-10 mM nicotinamide can be, for example, 2 mM, 2.5 mM, 3 mM, 3.5 mM, 4 mM, 4.5 mM, 5 mM, 5.5 mM, 6 mM, 6.5 mM, 7 mM, 7.5 mM, 8 mM, 8.5 mM, 9 mM, 9.5 mM, 10 mM or any value in the said range, which will not be described in detail due to space limitations.
[0083] In a preferred embodiment, the human amniotic fluid-derived organoid in vitro culture medium also includes a volume fraction of 0.1%-1% penicillin-streptomy, which serves the purpose of antibacterial during the culture process. The volume fraction of penicillin-streptomycin can be 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, 1% or any value in the range, which will not be repeated due to space limitations.
[0084] As a second aspect of the present invention, a method for culturing human amniotic fluid-derived organoids in vitro is provided, comprising the following steps:
[0085] Step 1: Primary culture:
[0086] Collecting human amniotic fluid cells, and adding the human amniotic fluid-derived organoid in vitro culture medium as described in the first aspect for culture, and obtaining primary amniotic fluid organoids after 10-14 days;
[0087] Step 2: Clone and create:
[0088] The culture medium of the primary amniotic fluid organoids was removed, ThypLE express enzyme was added for digestion, DMEM-F12 basal culture medium was added, and the organoid cell clusters were blown apart into single cells, filtered, resuspended, and counted, and then the human amniotic fluid-derived organoid in vitro culture medium as described in the first aspect was added for culture, and a successfully established organoid clone was obtained after 10-14 days;
[0089] Step 3: Subculture to obtain amniotic fluid organoids derived from single cells.
[0090] Among them, the number of days in step one can be 10d, 10.5d, 11d, 11.5d, 12d, 12.5d, 13d, 13.5d, 14d or any value in the range, which will not be elaborated again due to space limitations.
[0091] The number of days in step 2 may be 10d, 10.5d, 11d, 11.5d, 12d, 12.5d, 13d, 13.5d, 14d or any value within the range, which will not be described herein again due to space limitations.
[0092] In a preferred embodiment, the digestion temperature in step 2 is 36-40°C (for example, it can be 36°C, 36.5°C, 37°C, 37.5°C, 38°C, 38.5°C, 39°C, 39.5°C, 40°C or any value in the range, which will not be repeated due to space limitations), and the digestion time is 30-60min (for example, it can be 30min, 35min, 40min, 45min, 50min, 55min, 60min or any value in the range, which will not be repeated due to space limitations);
[0093] In a preferred embodiment, the filtration in step 2 is performed by filtering with a cell sieve having a pore size of 40-100 μm to obtain a cell suspension, the purpose of which is to remove incompletely digested cell clusters in the organoid cell suspension. The pore size of the cell sieve can be 40 μm, 45 μm, 50 μm, 55 μm, 60 μm, 65 μm, 70 μm, 75 μm, 80 μm, 85 μm, 90 μm, 95 μm, 100 μm or any value in the range, which will not be described in detail due to space limitations.
[0094] In a preferred embodiment, the resuspension in step 2 is to centrifuge the cell suspension, remove the supernatant, add DMEM-F12 basal culture medium, and then resuspend; wherein the centrifugation conditions are: 4°C, 1200rpm, 5 minutes.
[0095] In a preferred embodiment, the culture described in step 2 is specifically as follows: according to the cell counting results, a total of 100 single cells are taken and mixed thoroughly with pre-cooled 2.5 mL of matrix gel (Corning Matrigel matrix); 1 drop per well, 25 μL / well, is added to a 96-well plate, and the 96-well plate is transferred to an incubator for 20-30 minutes; after the matrix gel containing amniotic fluid cells is fully solidified, 150 μL of the human amniotic fluid-derived organoid in vitro culture medium as described in the first aspect is added to each well, and the culture medium is changed every 3 days.
[0096] In a preferred embodiment, the method for culturing human amniotic fluid-derived organoids in vitro comprises the following steps:
[0097] Step 1: Primary culture:
[0098] Collecting human amniotic fluid cells, and adding the human amniotic fluid-derived organoid in vitro culture medium described in any one of claims 1 to 4 for culturing, and obtaining primary amniotic fluid organoids after 10 to 14 days;
[0099] Step 2: Clone and create:
[0100] The culture medium of the primary amniotic fluid organoids was removed, ThypLE express enzyme was added for digestion, DMEM-F12 basal culture medium was added, and the organoid cell clusters were blown into single cells, and filtered with a cell sieve with a pore size of 40-100 μm; the cell suspension was centrifuged, the supernatant was removed, DMEM-F12 basal culture medium was added, and then the cell suspension was resuspended and counted, and then the in vitro culture medium of human amniotic fluid-derived organoids described in any one of claims 1 to 4 was added for culturing, and a successfully established organoid clone was obtained after 10-14 days;
[0101] Step 3: Subculture to obtain amniotic fluid organoids derived from single cells.
[0102] As a third aspect of the present invention, there is provided a use of the human amniotic fluid-derived organoid in vitro culture medium as described in the first aspect in the in vitro culture of human cell organoids.
[0103] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings.
[0104] Collection and pre-treatment of amniotic fluid:
[0105] Strictly follow the standard process and specifications for collecting amniotic fluid from pregnant women, and after confirming the basic information of the pregnant woman, including name, age, gestational age, etc., a professional doctor uses a sterile lumbar puncture needle to vertically puncture the amniotic cavity at the selected puncture point, slowly extract and collect about 20-30mL of amniotic fluid sample, and quickly inject the extracted amniotic fluid into a sterile sample bottle, seal it to prevent contamination, and use a 2-8℃ sample transport box to send the amniotic fluid sample to the laboratory environment for processing as soon as possible. The key information of the main reagents used in the specific implementation method is shown in Table 1.
[0106] Table 1 Information on the main reagents used in the specific implementation method
[0107]
[0108]
[0109] Example 1 Screening of Amniotic Fluid Organoid Culture Medium Components
[0110] First, the amniotic fluid sample was filtered using a 100 μm cell sieve in a biosafety cabinet to remove cell clusters and tissue fragments and retain the amniotic fluid cells. Subsequently, the filtered amniotic fluid cells were transferred to a centrifuge tube, mixed and a small amount of cell suspension was taken for counting, and the amniotic fluid cell sample was centrifuged at 300 g and 4 °C for 30 minutes.
[0111] Remove the supernatant, add Matrigel precooled at 4°C to resuspend the cells according to the cell count results, adjust the cell density to 120 amniotic fluid cells / uL, and evenly drop the amniotic fluid cells into the six-well plate at 25uL / drop, 6 drops / well, and carefully transfer the six-well plate to the incubator for 20 minutes. After the Matrigel solidifies, add 2mL of different formulas of human amniotic fluid-derived organoid in vitro culture medium to each well for culture. After that, change the medium every 3 days and observe the growth of amniotic fluid organoids under a microscope.
[0112] 1) Based on existing organoid culture literature, different amniotic fluid organoid formulations were prepared for testing, and the culture medium components of Schemes 1-10 were prepared according to the ingredients in Table 1.
[0113] The formulations of Schemes 1-10 all include the following components: basal medium DMEM / F12, B-27 supplement, 4-hydroxyethylpiperazineethanesulfonic acid, glutamine, WNT-3a, R-Spondin-1 and Noggin, and the concentrations of the components are shown in Table 2.
[0114] The order of adding other ingredients is to add them one by one for each scheme, with no other ingredients added in scheme 1, epidermal growth factor added in scheme 2, epidermal growth factor and A83-01 added in scheme 3, epidermal growth factor, A83-01 and gastrin added in scheme 4, epidermal growth factor, A83-01, gastrin and Y-27632 added in scheme 5, and so on.
[0115] Table 2: Amniotic fluid organoid culture medium formula for scheme 1-10
[0116]
[0117]
[0118] (+: means adding; -: means not adding.)
[0119] After 2 weeks of culture, the culture conditions of the amniotic fluid organoid culture media with different components were statistically analyzed, mainly including whether there was any growth of amniotic fluid organoids. The grown amniotic fluid organoids were digested and the cells were harvested for cell counting. Figure 1 It can be seen that there is no effective statistics on the number of amniotic fluid organoids in Schemes 1-3, indicating that the formula of epidermal growth factor, A83-01 and gastrin cannot meet the requirements of amniotic fluid organoid culture; Schemes 4-10 all have organoid growth, but the number of amniotic fluid organoids in Schemes 6-8 is not as good as that in Scheme 4-5, indicating that the addition of prostaglandin-E2 (starting from Scheme 6) may have an inhibitory effect on the growth of amniotic fluid organoids, while the addition of other ingredients can promote the growth of amniotic fluid organoids; Scheme 10 has the largest number of organoid cells, indicating that the added components are optimal.
[0120] 2) Based on the existing organoid culture literature, the formula of Scheme 10 was compared with the cell organoid culture medium from other sources shown in Table 3. After 2 weeks of culture, the culture conditions were statistically analyzed. The results showed that the culture effects of cell organoid culture medium from other cell sources were inferior to those of Scheme 10, indicating that the culture medium formula of Scheme 10 is more suitable for organoid culture of amniotic fluid cells.
[0121] Table 3 Main components of cell organoid culture medium from other cell sources
[0122]
[0123]
[0124] 3) In order to further verify the effects of prostaglandin-E2 and the special nutrient components CHIR99021, glial cell-derived neurotrophic factor, 8-Br-cAMP, and aldosterone added to amniotic fluid organoids on the culture effect of amniotic fluid organoids, on the basis of Scheme 4 (the most basic formula of amniotic fluid organoids obtained by preliminary screening), several combinations of culture media with CHIR99021, glial cell-derived neurotrophic factor, 8-Br-cAMP and / or aldosterone added alone or in combination were prepared to obtain a control group and Schemes 11-16 for verification. The specific schemes are shown in Table 4. The primary culture time, construction success rate, and final organoid cell number of the amniotic fluid organoids were detected and compared, with Scheme 4 as the control group.
[0125] Table 4: Amniotic fluid organoid culture medium formula for schemes 11-16
[0126]
[0127]
[0128] A total of 8 amniotic fluid samples were collected for this test. After arriving at the laboratory, the amniotic fluid samples were filtered using a 100μm cell sieve in a biosafety cabinet to remove cell clusters or tissue fragments and retain amniotic fluid cells. The filtered amniotic fluid cells were transferred to a centrifuge tube, mixed and a small amount of cell suspension was taken for counting, and the cell samples were centrifuged at 300g and 4°C for 30 minutes. The supernatant was removed, and according to the cell counting results, the cells were resuspended in Matrigel matrix gel that had been pre-cooled at 4°C, and the cell density was adjusted to 120 amniotic fluid cells / uL. The amniotic fluid cells were evenly dropped into a six-well plate at 25uL / drop and 6 drops / well, and 7 wells were plated for each amniotic fluid sample. The six-well plate was carefully transferred to the incubator for 20 minutes. After the Matrigel matrix gel solidified, 2mL of the above-mentioned human amniotic fluid-derived organoid in vitro culture medium was added to each well for culture. After 14 days of culture, the primary culture success rate of the amniotic fluid organoids and the number of organoid cells harvested were compared and analyzed.
[0129] The test results are shown in Table 5. It can be seen that compared with the control group (Scheme 4), the primary culture success rate of primary amniotic fluid organoids in Scheme 11 (adding prostaglandin-E2) dropped from 37.5% to 25%, and the number of organoid cells obtained decreased by about 34.5%. The primary organoid culture success rates of Schemes 12, 14, and 15 were no different from those of the control group, but the number of organoid cells obtained was significantly increased compared with the control group. Scheme 16 had the best effect, successfully constructing 7 primary amniotic fluid organoids out of 8 samples, and after 14 days of culture, the average number of cells in the harvested organoids was 6.95x10 5 , which was 3.23 times that of the control group.
[0130] Table 5: Recipes for primary amniotic fluid organoid culture using medium from Scheme 11-16
[0131]
[0132]
[0133] Based on the above results, the optimal composition of the in vitro culture medium for human amniotic fluid-derived organoids is: DMEM-F12 basal medium, B-27 supplement (minus vitamin A), 4-hydroxyethylpiperazineethanesulfonic acid, penicillin / streptomycin, nicotinamide, glutamine, WNT-3a, R-Spondin-1, Noggin, epidermal growth factor, A83-01, gastrin, Y-27632, CHIR 99021, glial cell line-derived neurotrophic factor, 8-Br-cAMP and aldosterone.
[0134] Example 2 Optimization of Amniotic Fluid Organoid Culture Medium Concentration
[0135] In order to further optimize the concentration of each component of the amniotic fluid organoid culture medium, according to the previous test results, prostaglandin-E2 that inhibits the growth of amniotic fluid organoids was removed, and the other components of the amniotic fluid organoid culture medium tested in Example 1 were screened and tested according to different component concentrations.
[0136] First, collect the cultured amniotic fluid organoids, use a 1mL pipette to mechanically break up the Matrigel matrix gel containing the organoids, add TrypLE express digestive enzyme, and digest in a 37°C water bath for 40 minutes. Then add 3-5mL of DMEM-F12 basal culture medium to fully disperse the organoid cell clusters into single cells. Filter the organoid cell suspension with a 100μm cell sieve, count the cells, and then centrifuge the filtered and collected cell suspension at 300g and 4°C for 5 minutes. Remove the supernatant and re-add the pre-cooled Matrigel matrix gel to adjust the density of the amniotic fluid organoids to 1*10 6 / mL. Add 1 drop per well, 25uL / well, to a six-well plate, and carefully transfer the six-well plate to an incubator for 20-30 minutes. Subsequently, 15 types of amniotic fluid organoid culture media from Schemes 17-31 were added, all of which were based on DMEM-F12 basal medium, with nutrients added in different concentration ranges according to Table 6. After 3 days of culture, the amniotic fluid organoids were recorded under a microscope, photographed, and the growth of the organoids was recorded. The results showed that schemes 17-31 all successfully obtained amniotic fluid organoids, among which the amniotic fluid organoids of Scheme 17-22 grew the slowest and were smaller, the amniotic fluid organoids of Schemes 26-31 grew relatively well, and the amniotic fluid organoids cultured in Schemes 23-25 had the best morphology and the largest number of organoids, which was the best human amniotic fluid-derived organoid in vitro culture medium formula among the tested schemes. Figure 2 These are pictures of organoid growth for Schemes 17, 20, 23, 26, and 29. It can be seen that Scheme 23 has the best growth, followed by Schemes 26 and 29, and Schemes 17 and 20 have the slowest growth. Schemes 18 and 19 have similar growth conditions to Scheme 17, Schemes 21 and 22 are similar to Scheme 20, Schemes 24 and 25 are similar to Scheme 23, Schemes 27 and 28 are similar to Scheme 26, and Schemes 30 and 31 are similar to Scheme 29.
[0137] Therefore, the optimal concentration of amniotic fluid organoid culture medium is:
[0138] The concentration of glial cell line derived neurotrophic factor is 100-200ng / mL; the concentration of 8-bromoadenosine-3',5'-cyclic monophosphate is 3-10μM; the concentration of aldosterone is 10-30nM; the concentration of 4-hydroxyethylpiperazineethanesulfonic acid is 10-50mM; the volume fraction of B-27 additive (minus vitamin A) is 1%-2%; the concentration of glutamine is 2-10mM; the concentration of WNT-3a is 200-500ng / mL; the concentration of R-Spondin-1 is 300-500ng / mL; the concentration of Noggin is 100-300ng / mL; the concentration of nicotinamide is 2-10mM. The concentration of CHIR99021 is 10-50 μM; the concentration of EGF is 100-300 ng / mL; the concentration of A83-01 is 5-20 μM; the concentration of gastrin is 5-20 nM; the concentration of Y-27632 is 10-20 μM; and the volume fraction of penicillin-streptomycin is 1%.
[0139] Table 6: Recipe for amniotic fluid organoid culture medium for Scheme 17-31
[0140]
[0141]
[0142] Example 3 Primary Culture of Amniotic Fluid Organoids
[0143] In this example, the culture process of amniotic fluid organoid scheme 23 was photographed and observed to track the growth of the organoids at each stage. Figure 3 This is a diagram of the growth status of amniotic fluid organoids at different culture times: it can be seen that at the beginning of culture (0 day), single cells can be observed, but no organoids; after 5 days of culture, it can be observed that some amniotic fluid organoids have grown out; after continuing to culture for several days, on the 10th day it can be seen that the number of amniotic fluid organoids has increased significantly, and the morphology has increased significantly; on the 14th day, the number and morphology of amniotic fluid organoids are already suitable for subculture.
[0144] Example 4 Establishment of Amniotic Fluid Organoid Clones
[0145] After the primary amniotic fluid organoids were successfully constructed in Example 3, the culture medium was removed from the primary amniotic fluid organoids, 1.5 mL of ThypLE express digestive enzyme and a final concentration of 2000 U / L of deoxyribonuclease were added, and the Matrigel matrix gel containing the organoids was mechanically broken up with a 1 mL pipette and placed in a 37°C water bath for digestion for 40 minutes. 3 mL of DMEM-F12 basal culture medium was added to fully disperse the organoid cell clusters into single cells.
[0146] Filter the organoid cell suspension with a 40μm cell sieve, take 300g of the filtered cell suspension, and centrifuge it at 4℃ for 5min. Remove the supernatant, re-add 5mL of DMEM-F12 basal medium to resuspend, count and dilute the cells, and draw 100 single cells into 2.5mL of Matrigel matrix gel pre-cooled at 4℃ and mix thoroughly. Add 1 drop per well, 25μL / well, to a 96-well plate, and carefully transfer the 96-well plate to the incubator for 20-30 minutes. After the matrix gel microspheres containing amniotic fluid cells are fully solidified, add 150μL of amniotic fluid organoid complete medium to each well. Change the medium every 3 days and culture for 10-14d.
[0147] After 10-14 days, observe and test under a microscope, and use a pipette to pick up the successfully cultured organoid clones for subculture to obtain several amniotic fluid organoid clones derived from single cells.
[0148] The amniotic fluid organoid clones in the 96-well plate were counted, and 34 normal amniotic fluid organoid clones were obtained among the 96 organoid clones planted, with a culture success rate of about 34%. Since only stem cells can eventually develop into organoids, this also suggests that the initially cultured amniotic fluid organoids contain a large number of other types of cells (non-stem cells), and clone selection methods are needed to obtain relatively pure amniotic fluid organoids. Figure 4 Four of the 34 amniotic fluid organoid clones successfully cultured from single cells are shown. No similar clones were observed in the culture medium that failed to be cultured. Figure 4 It can be seen that although the organoid clones of different amniotic fluid-derived cells can be successfully cultured, there are differences in growth morphology and growth rate, which also suggests that these organoids may have different biological characteristics and genetic backgrounds, which need further study.
[0149] Example 5 Differentiation of amniotic fluid organoids into neuronal cells
[0150] The digested amniotic fluid organoids were cloned at 0.5*10 6 / ml were inoculated into 12-well plates, and first added into amniotic fluid organoid complete medium for 3 days, and then replaced with neural stem cell induction differentiation medium. The formula of in vitro differentiation medium is:
[0151] The basal medium was supplemented with 2% B-27 supplement minus vitamin A, 2 mM glutamine, 2% N-2 supplement, and 20 ng / mL basic fibroblast growth factor, and differentiation was induced in vitro for 7 days.
[0152] Then replace the neuronal differentiation medium with the following formula: Culture medium, 20 ng / mL brain-derived neurotrophic factor (BDNF) and 20 ng / mL neurotrophin 3 (NT-3).
[0153] After 5 days of differentiation, the differentiated cells were collected and the expressions of neuronal cell-specific markers neurogenic differentiation factor 4 (Neurod4) and neuronal class III β-tubulin (Tuj1) were detected by RT-PCR. Figure 5 As shown, compared with the uninduced differentiation group, the mRNA expression levels of neurogenic differentiation factor 4 and neuronal class III β-tubulin increased by 17.81 times and 4.28 times, respectively, indicating that the amniotic fluid organoids are already in the process of neuronal cell differentiation. In the differentiation medium, the directed differentiation of amniotic fluid organoids into neuronal cells can be achieved, indicating that the amniotic fluid organoids constructed by the method of the present invention can successfully induce neuronal cell differentiation in a specific differentiation medium.
[0154] Example 6 Differentiation of amniotic fluid organoids into cardiomyocytes
[0155] The digested amniotic fluid organoids were cloned at 0.5*10 6 / ml were inoculated into 12-well plates, and first added into amniotic fluid organoid complete medium and continued to culture for 3 days, then the medium was removed and replaced with cardiomyocyte induction differentiation medium 1, the formula of which is:
[0156] DMEM-F12 basal medium was supplemented with 10% FBS and 2% B-27 supplement minus insulin, and differentiation was induced for 24 h.
[0157] Remove the culture medium and add differentiation induction medium 2, the formula is:
[0158] DMEM-F12 basal culture medium was supplemented with 10% FBS, 2% B-27 supplement minus insulin, 5uM IWR-1, and 5uM CHIR99021, and differentiation was continued for 48h.
[0159] Then change to induction medium 3, the medium formula is:
[0160] DMEM-F12 basal culture medium was supplemented with 10% FBS and 2% B-27 supplement minus insulin, and differentiation was continued for 7 days, after which the cardiomyocytes were harvested.
[0161] The cardiomyocytes finally harvested were subjected to RT-PCR to detect the expression of cardiomyocyte-specific marker genes Tbx5, GATA4, and α-MHC. Figure 6 and Figure 7 As shown, compared with the uninduced differentiation group, the mRNA expression levels of cardiomyocyte-specific marker genes T-box transcription factor 5 (Tbx5), GATA binding protein 4 (GATA4), α-myosin heavy chain (α-MHC) and homeobox transcription factor NKX2.5 (Nkx2.5) increased by 349.98 times, 705.26 times, 24.97 times and 69.07 times, respectively, indicating that the amniotic fluid organoids are in the process of differentiating into cardiomyocytes. In the differentiation medium, the directed differentiation of amniotic fluid organoids into cardiomyocytes can be achieved, indicating that the amniotic fluid organoids constructed by the method of the present invention can successfully induce cardiomyocyte differentiation in a specific differentiation medium.
[0162] In summary, the in vitro culture method of human amniotic fluid-derived organoids provided by the present invention is simple to operate, the components of the in vitro culture medium of human amniotic fluid-derived organoids are clear, and the culture success rate is high. The human amniotic fluid organoids cultured using the culture medium and method of the present invention can be differentiated into multiple types of functional cells including neuron-like cells, cardiomyocytes, etc. after induction in vitro, and the differentiation ability is significantly better than the existing 2D cell line model. In addition, the single-cell-derived amniotic fluid organoid model constructed by the method of the present invention can be stably propagated for a long time, and is suitable as an in vitro research model for studying early developmental diseases of the human fetus.
[0163] The specific embodiments described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. An in vitro culture medium for human amniotic fluid-derived organoids, characterized in that: Includes the following ingredients: Glial cell line-derived neurotrophic factor, 8-bromoadenosine-3',5'-cyclic monophosphate, and aldosterone.
2. The human amniotic fluid-derived organoid in vitro culture medium according to claim 1, characterized in that: The concentration of glial cell line-derived neurotrophic factor is 100-200 ng / mL; and / or The concentration of 8-bromoadenosine-3',5'-cyclic monophosphate is 3-10 μM; and / or The concentration of aldosterone was 10-30 nM.
3. The human amniotic fluid-derived organoid in vitro culture medium according to claim 1, characterized in that: Also includes: DMEM-F12 basal medium, 4-hydroxyethylpiperazineethanesulfonic acid, B-27 supplement-minus vitamin A, glutamine, WNT-3a, R-Spondin-1 protein, Noggin protein, and nicotinamide.
4. The human amniotic fluid-derived organoid in vitro culture medium according to claim 3, characterized in that: The concentration of 4-hydroxyethylpiperazineethanesulfonic acid is 10-50 mM; and / or B-27 supplement - minus 1% to 2% vitamin A; and / or Glutamine at a concentration of 2-10 mM; and / or The concentration of WNT-3a is 200-500 ng / mL; and / or The concentration of R-Spondin-1 is 300-500 ng / mL; and / or The concentration of Noggin protein is 100-300 ng / mL; and / or The concentration of nicotinamide was 2-10 mM.
5. The human amniotic fluid-derived organoid in vitro culture medium according to claim 1, characterized in that: Also includes: CHIR 99021, epidermal growth factor, A83-01, gastrin, and Y-27632; and / or Penicillin-streptomycin.
6. The human amniotic fluid-derived organoid in vitro culture medium according to claim 5, characterized in that: The concentration of CHIR99021 is 10-50 μM; and / or The concentration of epidermal growth factor is 100-300 ng / mL; and / or A83-01 is at a concentration of 5-20 μM; and / or The concentration of gastrin is 5-20 nM; and / or The concentration of Y-27632 is 10-20 μM; and / or The volume fraction of penicillin-streptomycin is 0.1%-1%.
7. A method for culturing human amniotic fluid-derived organoids in vitro, characterized in that: The following steps are involved: Step 1: Primary culture: Collecting human amniotic fluid cells, and adding the human amniotic fluid-derived organoid in vitro culture medium described in any one of claims 1 to 4 for culturing, and obtaining primary amniotic fluid organoids after 10 to 14 days; Step 2: Clone and create: The culture medium of the primary amniotic fluid organoids was removed, ThypLE express enzyme was added for digestion, DMEM-F12 basal culture medium was added, and the organoid cell clusters were blown into single cells, filtered, resuspended, and counted, and then the human amniotic fluid-derived organoid in vitro culture medium according to any one of claims 1 to 4 was added for culture, and a successfully established organoid clone was obtained after 10 to 14 days; Step 3: Subculture to obtain amniotic fluid organoids derived from single cells.
8. The method for in vitro culture of human amniotic fluid-derived organoids according to claim 7, characterized in that: The digestion temperature in step 2 is 36-40°C and the digestion time is 30-60 min; and / or The filtration in step 2 is performed by filtering with a cell sieve having a pore size of 40-100 μm to obtain a cell suspension; and / or The resuspension in step 2 is to centrifuge the cell suspension, remove the supernatant, add DMEM-F12 basal culture medium, and then resuspend.
9. The method for in vitro culture of human amniotic fluid-derived organoids according to claim 7 or 8, characterized in that: The method comprises the following steps: Step 1: Primary culture: Collecting human amniotic fluid cells, and adding the human amniotic fluid-derived organoid in vitro culture medium described in any one of claims 1 to 4 for culturing, and obtaining primary amniotic fluid organoids after 10 to 14 days; Step 2: Clone and create: The culture medium of the primary amniotic fluid organoids was removed, ThypLE express enzyme was added for digestion, DMEM-F12 basal culture medium was added, and the organoid cell clusters were blown into single cells, and filtered with a cell sieve with a pore size of 40 μm-100; the cell suspension was centrifuged, the supernatant was removed, DMEM-F12 basal culture medium was added, and then the cell suspension was resuspended and counted, and then the in vitro culture medium of human amniotic fluid-derived organoids according to any one of claims 1 to 4 was added for culturing, and a successfully established organoid clone was obtained after 10 to 14 days; Step 3: Subculture to obtain amniotic fluid organoids derived from single cells.
10. Use of the human amniotic fluid-derived organoid in vitro culture medium according to any one of claims 1 to 6 in the in vitro culture of human cell organoids.
Citation Information
Patent Citations
machine for the production of mosaic panels from rows of blocks grooved on two sides and held together by interposed springs
CH27632A
Application of amniotic fluid stem cells in the preparation of drugs for treating lupus nephritis
CN111759864B
